Rob Rentenaar

Dr. Rob Rentenaar

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
RCRuth Alexandra Corrigan
Ruth Alexandra Corrigan
JSJonathan Sliepen
Jonathan Sliepen
MDMaria Dudareva
Maria Dudareva
FIFrank IJpma
Frank IJpma
GGGeertje Govaert
Geertje Govaert
MMMartin A McNally
Martin A McNally
Fracture-related infections (FRIs) are classically considered to be early (0–2 weeks), delayed (3–10 weeks) or late (>10 weeks) based on hypothesized differences in causative pathogens and biofilm formation. Treatment strategies often reflect this classification, with debridement, antimicrobial therapy and implant retention (DAIR) preferentially reserved for early FRI. This study examined pathogens isolated from FRI to confirm or refute these hypothesized differences in causative pathogens over time. Cases of FRI managed surgically at three centres between 2015–2019 and followed up for at least one year were included. Data were analysed regarding patient demographics, time from injury and pathogens isolated. Patients who underwent DAIR were also analysed separately. In total, 433 FRIs were studied, including 51 early cases (median time from injury of 2 weeks, interquartile range (IQR) of 1–2 weeks), 82 delayed cases (median time from injury of 5 weeks, IQR of 4–8 weeks) and 300 late cases (median time from injury of 112 weeks, IQR of 40–737 weeks). The type of infection was associated with time since injury; early or delayed FRI are most likely to be polymicrobial, whereas late FRIs are more likely to be culture-negative, or monomicrobial. Staphylococcus aureus was the most commonly isolated pathogen at all time points; however, we found no evidence that the type of pathogens isolated in early, delayed or late infections were different (p = 0.2). More specifically, we found no evidence for more virulent pathogens (S. aureus, Gram-negative aerobic bacilli) in early infections and less virulent pathogens (such as coagulase negative staphylococci) in late infections. In summary, decisions on FRI treatment should not assume microbiological differences related to time since injury. From a microbiological perspective, the relevance of classifying FRI by time since injury remains unclear.

29 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
JSJonathan Sliepen
Jonathan Sliepen
RCRuth Alexandra Corrigan
Ruth Alexandra Corrigan
MDMaria Dudareva
Maria Dudareva
MWMarjan Wouthuyzen-Bakker
Marjan Wouthuyzen-Bakker
RRRob Rentenaar
Rob Rentenaar
FIFrank IJpma
Frank IJpma
This international, multi-center study evaluated the effect of antibiotic-loaded carriers (ALCs) on outcome in patients with a fracture-related infection (FRI) and evaluated whether bacterial resistance to the implanted antibiotics influences their efficacy. All patients who were retrospectively diagnosed with FRI according to the FRI consensus definition, between January 2015 and December 2019, and who underwent surgical treatment for FRI at any time point after injury, were considered for inclusion. Patients were followed-up for at least 12 months. The primary outcome was the recurrence rate of FRI at follow-up. Inverse probability for treatment weighting (IPTW) modeling and multivariable regression analyses were used to assess the relationship between the application of ALCs and recurrence rate of FRI at 12 months and 24 months. Overall, 429 patients with 433 FRIs were included. A total of 251 (58.0%) cases were treated with ALCs. Gentamicin was the most frequently used antibiotic (247/251). Recurrence of infection after surgery occurred in 25/251 (10%) patients who received ALCs and in 34/182 (18.7%) patients who did not (unadjusted hazard ratio (uHR): 0.48, 95% CI: [0.29–0.81]). Resistance of cultured microorganisms to the implanted antibiotic was not associated with a higher risk of recurrence of FRI (uHR: 0.75, 95% CI: [0.32–1.74]). The application of ALCs in treatment of FRI is likely to reduce the risk of recurrence of infection. The high antibiotic concentrations of ALCs eradicate most pathogens regardless of susceptibility test results.

13 July 2022 in Acta Orthopaedica
Verified
Journal Article
Open access
PDF file
BDBruce Van Dijk
Bruce Van Dijk
RNRuben Nurmohamed
Ruben Nurmohamed
JDJ Fred F Hooning van Duijvenbode
J Fred F Hooning van Duijvenbode
EVEwout S. Veltman
Ewout S. Veltman
RRRob Rentenaar
Rob Rentenaar
BWBart C H Van der Wal
Bart C H Van der Wal
Background and purpose: The long-term results of the 1- or 2-stage revision procedure and infection-free prosthesis survival in a tertiary referral center are unknown. In this retrospective observational study, the long-term results of infection control and infection-free prosthesis survival of the periprosthetic joint infection-related 1- and 2-stage revision procedure are evaluated. Furthermore, the merits of performing an antibiotic-free window in the 2-stage revision is evaluated.Patients and methods: All patients who received a 1- or 2-stage revision procedure of the hip or knee between 2010 and 2017 were included. Data was collected on patient and infection characteristics. The primary treatment aim was successful infection control without the use of antibiotic therapy afterwards. Infection-free survival analysis was performed using the Kaplan–Meier method with type of periprosthetic joint infection-related revision as covariate. Within the group of 2-stage revisions, use of an antibioticfree window was selected as covariate.Results: 128 patients were treated for a periprosthetic joint infection-related revision procedure (81 hips and 47 knees). Successful infection control was achieved in 18 of 21 cases for the 1-stage and 89 out of 107 cases for the 2-stage revision procedure (83%) respectively after follow-up of more than 4 years. In addition, 2-stage revision procedure infection control was achieved in 52 of 60 cases with an antibiotic-free interval and 37 of 45 cases without such interval (p = 0.6). The mean infection-free survival of the 1-stagerevision was 90 months (95% CI 75–105) and 98 months (CI 90–106) for the 2-stage revision procedure.Interpretation: There seems to be no difference in infection control and infection-free survival between the 1- and 2-stage revision procedure. Second, an antibiotic-free window in the case of a 2-stage revision did not seem to influence treatment outcome. However, one must be cautious when interpreting these results due to confounding by indication and the small study population. Therefore, no definite conclusion can be drawn.

1 January 2018 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
RRRob Rentenaar
Rob Rentenaar
SKStijn M. Kusen
Stijn M. Kusen
GZG. M. A. Riemens-Van Zetten
G. M. A. Riemens-Van Zetten
MMMaaike S.M. van Mourik
Maaike S.M. van Mourik
Cutibacterium acnes (reclassification of Propionibacterium acnes) is considered an organism of low pathogenicity (1).…

1 June 2021 in Anaerobe
Verified
Journal Article
Open access
RRRob Rentenaar
Rob Rentenaar
BBBianca Bovo-Heijmans
Bianca Bovo-Heijmans
JDJoanna Diggle
Joanna Diggle
AFAd C. Fluit
Ad C. Fluit
MWMandy Wootton
Mandy Wootton
Repeatedly, too low MIC results were obtained in Bacteroides fragilis quality assessment strains, using gradient strip tests with a ratio of amoxicillin:clavulanic acid of 2:1. We aimed to find the most accurate available gradient strip tests for susceptibility testing of amoxicillin/clavulanic acid in B. fragilis in comparison with agar dilution with EUCAST methodology and breakpoints. Twenty-seven clinical B. fragilis isolates were investigated using gold standard EUCAST amoxicillin/clavulanic acid agar dilution (fixed clavulanic acid concentration at 2 mg/L, with increasing amoxicillin concentrations) as well as three commercial gradient strip tests: XL (ratio), AUG (ratio) or AMC (fixed concentration). Using agar dilution (fixed concentration), 19 isolates were susceptible, 1 isolate was susceptible increased exposure (I) and 7 isolates were resistant. Categorical agreement of the gradient strip tests with agar dilution (fixed concentration) was 70% for XL (ratio), 71% for AUG (ratio) and 89% for AMC (fixed concentration). Very major error rates in comparison with agar dilution (fixed concentration) were 100%, 0%, and 0%, respectively. EUCAST breakpoint usage in amoxicillin/clavulanic acid susceptibility tests for B. fragilis should be accompanied by EUCAST methodology. When using alternative methods such as gradient strip tests, a higher degree of alignment with EUCAST methodology, such as using fixed clavulanic acid concentrations, improves precision.

1 April 2019 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
AFAd C. Fluit
Ad C. Fluit
RRRob Rentenaar
Rob Rentenaar
MEMiquel B. Ekkelenkamp
Miquel B. Ekkelenkamp
TSTim T. Severs
Tim T. Severs
AMAnnelies M. C. Mavinkurve-Groothuis
Annelies M. C. Mavinkurve-Groothuis
TWTom F. W. Wolfs
Tom F. W. Wolfs
A 13-year old neutropenic boy succumbed to bacteremia and sepsis with a Pseudomonas aeruginosa strain that rapidly developed resistance to carbapenems during meropenem monotherapy. Whole genome sequencing of the susceptible and resistant blood culture isolates revealed the meropenem-resistant phenotype to be caused by truncation of the OprD gene, which added to a preexisting inactivated mexR gene.